JERUSALEM, Dec. 14 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. recently presented at both the Equities Magazine Conference held at the Yale Club and the Wall Street Analyst Forum at Princeton Club in New York. Due to the interest in alternative delivery systems, Oramed compared the benefits of their oral insulin capsule in contrast to another popular insulin delivery system that is entering the market -- the insulin inhaler.
During Oramed's presentation at the Wall Street Analyst Forum, Dr. Miriam Kidron, Oramed's Chief Technology Officer, was asked to comment on the comparison of Oramed's insulin capsule versus an insulin inhaler. Dr. Kidron responded, "There is no comparison. The inhaler was designed in an effort to mimic the effects of subcutaneous insulin, which is not physiologically natural. Insulin should not be delivered directly into the bloodstream. Oramed's capsule provides a better physiological entry for insulin." Dr. Kidron was asked if she thought that diabetics were afraid to take the needle. To that question she responded, "Some diabetics may be fearful of the needles, but millions are injecting themselves daily, including some who inject multiple times daily. The significance of Oramed's insulin differentiates it from the rest of the insulin products because it administers the insulin to the body via the portal vein, which then supplies the liver with insulin rather than directly to the bloodstream.
Dr. Kidron continued, "In essence, oral insulin is an innovative technology, not just because it removes the necessity for the patient to use needles, but also helps improve their physiological health over time."
About Oramed Pharmaceuticals, Inc:
Oramed Pharmaceuticals' is an Israeli based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimen. Oramed is currently developing an orally soft gel insulin capsule for the treatment of diabetes. The Company is also pursuing the development of oral delivery solutions for other drugs and vaccines.
For more information on Oramed Pharmaceuticals please visit our website at http://www.oramedpharma.com and view the latest article written on Oramed Pharmaceuticals in Equities Magazine.
Investor Relations Contact: Oramed Pharmaceuticals, Inc. Vinisha Agnihotri (646) 467-2252 info@oramedpharma.comhttp://www.oramedpharma.com Legal Notice Regarding Forward Looking Statements
This news release contains statements, which may constitute "forward- looking statements". Those statements include statements regarding the intent, belief or current expectations of Oramed Pharmaceutical Inc., and members of our management as well as the assumptions on which such statements are based. Forward-looking statements in this release include: that oral insulin will become very popular; that oral insulin would improve the physiological health of patients; that we are currently developing an orally ingestible soft gel insulin capsule for the treatment of diabetes and for other diseases. Factors which may significantly change or prevent our forward looking statements from fruition include that oral insulin gel capsules may not be suitable for our intended purposes ; we may be unsuccessful in developing any products; we may be unable to raise funds and resources to pursue research and development; we may be unable to successfully defend our patents from infringement by third parties, there is a risk that our patents may be subsequently shown to be invalid or infringe the patents of others, our products may never gain FDA or other regulatory body approval for human consumption and we may be unable to successfully commercialize our future products. Readers should refer to our most recent 10-KSB filed on Edgar and the 8-K announcing our acquisition of the Oramed technology filed March 8, 2006.
Oramed Pharmaceuticals, Inc.CONTACT: Vinisha Agnihotri, Oramed Pharmaceuticals, Inc., +1-646-467-2252,info@oramedpharma.com
Web site: http://www.oramedpharma.com/
